KRAS and malignant colon neoplasm: Intriguingly, unlike previous reports, the direct identification of neoantigens with a representative cancer driver mutation, an oncogenic KRAS, from the terminal stage of colon cancer tissue was achieved by an established DIM-MS-based global-immunopeptidomics approach.